The Solo-Founded Telehealth Wave: Why One-Person GLP-1 Brands Out-Earned $1B Incumbents in 2025

Medvi is the headline. The category is the story.

Updated 2026-04-17

Revenue

Collectively into the billions; Medvi alone at $401M in 2025, projected $1.8B in 2026

Employees

Typically 1-5, with licensed services outsourced

Industry

Direct-to-consumer telehealth (GLP-1, ED, hair loss, skin, mental health)

Founder

Multiple — Matthew Gallagher (Medvi) is the most visible example

Timeline

2022-2023Post-Ozempic GLP-1 demand goes mainstream. Hims & Hers and Ro reach ~$2.4B and ~$750M in revenue respectively, with thousands of employees between them. The market is not saturated — it is underserved.
Early 2024Telehealth orchestration platforms like OpenLoop and CareValidate mature. They let any founder plug into a full clinical + pharmacy + e-prescribing stack without building it.
Mid 2024First wave of solo founders (Matthew Gallagher among them) start DTC GLP-1 brands. AI tooling (ChatGPT, Claude, Grok) removes the need for in-house copy, code, and support teams.
Late 2024Paid social on social and TikTok becomes the default acquisition channel. Creator whitelisting gives solo founders the scale of ad accounts that used to require full media-buying teams.
2025Medvi reaches $401M in its first full year. Multiple adjacent solo brands follow the same playbook at smaller scale in ED, hair loss, mental health, and skincare.
December 2025FDA warning letters and state-board scrutiny begin landing on the category. The cash-pay GLP-1 wave matures faster than regulators anticipated.
Q1 2026NYT, PYMNTS, Inc., Fortune, and eWeek feature solo-founded telehealth as the clearest example of AI-enabled solo scaling. The regulatory conversation catches up.

Key insights

  • 01Demand shape is everything. The cash-pay, recurring-prescription, broadly-advertisable categories (GLP-1, ED, hair loss, skin, sleep, mental health) are structurally well-suited to solo founders.
  • 02Incumbents built scale before AI tooling collapsed the headcount requirement. Their operating cost is now a strategic disadvantage against new entrants.
  • 03Outsourced clinical infrastructure is the unsexy enabler. OpenLoop and CareValidate are the 'Stripe' of telehealth for solo founders.
  • 04Paid social at scale is now operable by one person with AI — creative volume, ad ops, landing page testing, and reporting all fit inside a single operator's day.
  • 05Margin compression will come. Early solo entrants enjoy 15-20%+ net margins; by 2027-2028 competition and regulation will likely squeeze those to 5-10% across the category.
  • 06Regulation is the real ceiling. Hims & Hers and Ro invested years in clinical governance; solo founders can match their unit economics but not their compliance depth, which is exactly where enforcement will focus.
  • 07The category is a template, not an endpoint. The same operating pattern (outsourced licensed services + AI-run ops + paid social) is starting to move into legal, accounting, and financial advice — slower, because regulators are more alert, but directionally similar.

Stack used

OpenLoop or CareValidate for telehealth orchestration503A/503B compounding pharmacies as fulfillment partnerssocial ads + TikTok Ads with creator whitelistingStripe for subscription billingChatGPT, Claude, Grok for creative, code, copy, and supportCloud-hosted landing pages (Next.js, Vercel) with server-side analyticsCustomer-service AI with human escalationFinance stack (Xero, QuickBooks) closed monthly with AI assistanceAffiliate and creator networksCompliance-review tooling (increasingly important post-FDA letters)

What this means for you

  • If you are going to solo-scale in a regulated category, treat compliance as product. Build it in before you build ads.
  • Outsource the licensed parts to an orchestrator. Do not try to hire a medical director, build pharmacy relationships, and run ads in the same week.
  • Pick a category where the patient pays cash monthly. Insurance-driven businesses have entirely different unit economics and do not fit the solo pattern.
  • Expect regulators to arrive 12-18 months late. Plan the compliance stack for the day they do, not the day you launch.
  • Watch for adjacent, less-regulated categories. Skincare, sleep, supplements, and cash-pay diagnostics are smaller markets but easier first launches.
  • Understand that headcount compression is the product. The reason Medvi beats Hims on margin is not branding — it is ~1,000x fewer employees.
FAQ

Frequently asked questions

Clear answers about wallet credit, usage, subscriptions, and how Tycoon charges for work.

Is every telehealth brand launching in 2025-2026 actually solo-founded?

No, but the pattern is surprisingly common in specific sub-segments. The clearest examples are in GLP-1 cash-pay, where a single operator can plug into a telehealth orchestrator and a pharmacy network on day one. Categories that require in-house licensed providers (complex mental health, surgery, insurance-billed primary care) still require more infrastructure and headcount. The generalization is: wherever 'licensed service as a partner' is available, solo telehealth is possible. Wherever it is not, it is not.

How can a solo founder realistically run a $400M+ telehealth business?

By not doing the work a traditional $400M telehealth business does. Solo founders do not run clinics, operate pharmacies, or employ large customer service teams. They operate a funnel: creative, ad ops, landing page, intake, and hand-off. Everything downstream is outsourced to partners who already do it at scale. Matthew Gallagher himself has publicly stated that ChatGPT, Claude, and Grok handle most of what used to be a marketing and ops department. The math works because the operator does 1-2% of the actual work of the business and collects the equity upside.

What does the FDA warning letter against Medvi mean for the category?

It means the cash-pay GLP-1 wave has matured fast enough to draw real regulatory attention. The December 2025 warning letter flagged specific claims and labeling issues (for example, text implying Medvi itself was the compounder when it is not, or marketing that equated Medvi's compounded product with Wegovy and Ozempic). For the category broadly, this signals that marketing claims, prescriber oversight, and pharmacy disclosures will be the next battleground. Solo founders who want to survive must invest in compliance as rigorously as they invest in paid acquisition.

Can this pattern move to other verticals?

It is already starting to. Cash-pay primary care concierge services, online mental-health support, cosmetic dermatology, and certain supplement and nutrition categories are seeing solo-founded experiments with similar outsourcing patterns. Outside healthcare, the closest analogs are in legal services (LLC formation, trademark filing), tax and accounting (for small businesses), and some financial advice — each with its own regulator problem. The unlock is always the same: a 'platform partner' that handles the licensed part so the operator can focus on funnel and funding.

What would a Series A-backed competitor do to stop a solo Medvi-style brand?

Three things, if they were competent. First, aggressively defend brand search and review sites so that a Medvi-like newcomer cannot hijack their traffic. Second, ship faster cross-channel creative — the solo brands are winning on creative volume, and funded teams can technically match or exceed that with the right structure. Third, work with regulators proactively to establish clinical governance standards that small operators cannot meet. Hims and Ro are attempting versions of all three; the results over the next 18 months will determine whether the category stays solo-operable at scale.

Related resources

One-person company

Medvi: $20K to $401M in 12 Months

Matthew Gallagher built Medvi from a $20K check to $401M revenue in its first year with AI. Here is exactly how.

One-person company

Polsia: $0 to $10.4M ARR, $30M Raise, Then a Decline

Ben Cera launched Polsia Dec 2025. 8,509 autonomous companies, $10.4M ARR, $30M Series A at $250M — then ARR dropped 3% in a week. The full breakdown.

One-person company

Pieter Levels: $3M/yr Solo, 0 Employees

Pieter Levels built 70+ projects, 3 of them past $38K MRR each, solo since 2014. The original one-person company playbook.

Playbook

The One-Person Billion-Dollar Company Playbook (2026)

Sam Altman predicted it. Matthew Gallagher proved it with Medvi's $1.8B projected 2026. Here's the playbook — market, stack, execution, milestones.

Playbook

Reach $1M ARR Solo: The Playbook (2026)

The systematic path from $0 to $1M ARR as a solo founder in 2026. Category picks, stack, milestones, numbers that actually work.

Pillar

Run a One-Person Company With a Full AI Workforce (2026)

Build a one-person company with an AI workforce manager that gives you a CEO, CMO, CTO, COO, and operators. No hires, no freelancers — just you and an AI team.

Stop managing agents. Just describe outcomes.

Tycoon Agent manages all your agents. Set her up in 30 seconds, free.

Free to start · No credit card required · Set up in 30 seconds